Ocular vascular thrombotic events: central retinal vein and central retinal artery occlusions.
We prospectively assessed associations of thrombophilia- hypofibrinolysis with central retinal vein occlusion (CRVO) (40 patients) and central retinal artery occlusion (CRAO) (9 patients). We used polymerase chain reaction measures for thrombophilia (factor V Leiden, prothrombin, C677T MTHFR, platelet glycoprotein PlA1/A2) and hypofibrinolysis (plasminogen activator inhibitor-1 4G4G). Serologic thrombophilia measures included protein C, protein S (total and free) and antithrombin III, homocysteine, lupus anticoagulant, anticardiolipin antibodies IgG-IgM, and factors VIII and XI. Serologic hypofibrinolysis measures included Lp(a) and plasminogen activator inhibitor activity. For comparison with 40 CRVO and 9 CRAO patients, 80 and 45 race-gender matched controls were studied. The factor V mutation was more common in CRVO (3/40, 8%) than controls (0/79, 0%), P = .036, as was high (>150%) factor VIII (12/40, 30%) versus (4/77, 5%), P = .0002. Low antithrombin III (<80%) was more common in CRVO (5/39, 13%) than in controls (2/73, 3%), P = .049. Homocysteine was high (> or =13.5 micromol/L) in 5/39 (13%) CRVO patients versus 2/78 controls (3%), P = .04. Three of 9 CRAO patients (33%) had low (<73%) protein C versus 2/37 controls (5%), P = .044. Two of 9 CRAO patients (22%) had high (> or =13.5 micromol/L) homocysteine versus 0/42 controls (0%), P =. 028. Four of 9 CRAO patients had the lupus anticoagulant (44%) versus 4/33 (12%) controls (P = .050). CRVO is associated with familial thrombophilia (factor V Leiden, factor VIII, low antithrombin III, homocysteinemia), and CRAO is associated with familial and acquired thrombophilia (low protein C, homocysteinemia, lupus anticoagulant), providing avenues for thromboprophylaxis, and triggering family screening.
Glueck
Charles J
CJ
Jewish Hospital Cholesterol Center, Cincinnati, OH 45229, USA. glueckch@healthall.com
Ping Wang
Hutchins
Robert
R
Petersen
Michael R
MR
Golnik
Karl
K
D000328:Adult; D000368:Aged; D050197:Atherosclerosis / Q000097:blood / Q000209:etiology / Q000235:genetics; D016022:Case-Control Studies; D005165:Factor V / Q000235:genetics; D005260:Female; D005342:Fibrinolysis / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000097:blood / Q000235:genetics; D011250:Pregnancy Complications, Hematologic / Q000097:blood / Q000235:genetics; D011256:Pregnancy Outcome; D011446:Prospective Studies; D012161:Retinal Artery; D015356:Retinal Artery Occlusion / Q000097:blood / Q000209:etiology* / Q000235:genetics; D012170:Retinal Vein Occlusion / Q000097:blood / Q000209:etiology* / Q000235:genetics; D012307:Risk Factors; D019851:Thrombophilia / Q000097:blood / Q000150:complications / Q000235:genetics; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000235:genetics
C095381:factor V Leiden; D005165:Factor V